Advanced algorithmic thinking
Principal Engineer coding rounds test optimization skills, complex data structures, and ability to discuss trade-offs at scale.
0 roles from funded startups and hidden sources. Posted
minutes ago. Updated every 60 seconds
Principal Engineer interviews focus heavily on architectural thinking, technical leadership, and cross-team collaboration skills.. Explore key insights and preparation tips to help you excel in your interview process.
Principal Engineer coding rounds test optimization skills, complex data structures, and ability to discuss trade-offs at scale.
Design distributed systems handling millions of users, with focus on reliability, scalability, and operational excellence.
Distributed Systems
Multi-region architectures
Microservices
Service mesh & observability
Data Architecture
Event-driven systems
Companies evaluate your ability to drive technical strategy, mentor teams, and influence engineering culture.
Meta
Cross-functional leadership and infrastructure scaling
Stripe
Technical decision-making and platform architecture
Compare cost-of-living buying power and how crowded the market is versus other major tech cities—so you can focus your search where the odds fit your goals.
Baltimore offers 65% lower housing costs compared to San Francisco, with median home prices around $200K versus SF's $1.4M. Principal Engineers can achieve homeownership and build wealth while maintaining competitive salaries in the $180K-220K range, delivering superior ROI on their technical expertise.
Baltimore's Principal Engineer market shows 28% saturation versus 78% in San Francisco. Growing demand from cybersecurity firms, biotech companies, and federal contractors creates abundant opportunities.

New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job postsPearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
Raised
$11.2M
Series A · 2026
Key contacts
-
Leadership & hiring contacts indexed
HQ market
Baltimore, Maryland
United States